Organic and inorganic growth potential from rising demand in the healthcare sector
€106.4mn
Equity investment
€83mn
Revenues 2019 (pro forma, exp.)
632
Employees 2019

KEY FACTS AT A GLANCE

  • Full range service provider in the fields of radiology and nephrology
  • Further expansion of Excellence Medicine
  • Potentials through an organic and inorganic growth strategy

BLIKK HOLDING GMBH

Investment by
DBAG FUND VII

€106.4MN

DBAG'S INTEREST

€19.0MN

MANAGEMENT BUYOUT
Shareholders:
DBAG FUND VII

60.9%

EQUITY SHARE BELONGING TO DBAG

10.9%

other shareholders

39.1%

First invested

MAY 2019

REVENUES in €mn

 

57

 

2017 (pro forma)

 

75

 

2018 (pro forma)

 

83

 

2019 (PRO FORMA, EXP.)

As of 31 December 2019

5

add-on acquisitions closed within holding period

The blikk Group is already the market leader in Germany in terms of the number of radiological examinations and findings. We are investing in a dynamic, innovative company with great growth potential and a clear strategic roadmap.

LUCAS HERBERT
MANAGING DIRECTOR

PROFILE

The blikk Group merges radiology, nuclear medicine and nephrology, thus making a major contribution towards ensuring top-class medical care. Group practices act as innovative partners for patients, physicians and cooperating hospitals.

Their pioneering role in closely combining outpatient and inpatient care is rooted in many years of collaborative experience with hospitals, offering both inpatient and outpatient imaging and nuclear medicine diagnostics to patients.

Managed by operasan GmbH, the nephrology business provides patients with the complete range of modalities and treatments, including dialysis.

blikk leverages ground-breaking technologies, equipment and methods and is continuously expanding its capacities and range of medical disciplines. The Group is well positioned to tackle the challenges arising from demographic change, technological disruption and new diseases. Key competitive differentiators include the practices’ ability to provide top-class imaging and diagnostics as well as highly efficient processes and appointments at short notice.

POTENTIAL FOR DEVELOPMENT

The blikk Group merges radiology, nuclear medicine and nephrology, thus making a major contribution towards ensuring top-class medical care. Group practices act as innovative partners for patients, physicians and cooperating hospitals.

Their pioneering role in closely combining outpatient and inpatient care is rooted in many years of collaborative experience with hospitals, offering both inpatient and outpatient imaging and nuclear medicine diagnostics to patients.

Managed by operasan GmbH, the nephrology business provides patients with the complete range of modalities and treatments, including dialysis.

blikk leverages ground-breaking technologies, equipment and methods and is continuously expanding its capacities and range of medical disciplines. The Group is well positioned to tackle the challenges arising from demographic change, technological disruption and new diseases. Key competitive differentiators include the practices’ ability to provide top-class imaging and diagnostics as well as highly efficient processes and appointments at short notice.

FINANCIAL YEAR 2019

In 2019, the Group continued its expansion by acquiring another dialysis practice and a highly specialized regional hospital in Berlin. As the majority of the hospital's revenues are generated from outpatient examinations or treatments with a focus on radiological services, it is an excellent strategic fit with blikk; it will act as the core of blikk's future buy-and-build strategy. Group sales and profits should be above the level of the previous year, in particular due to the acquisitions of further radiology practices which have now been completed and which for the first time contributed to sales and profits for a full year. Furthermore, the management team launched a new state-of-the-art radiology centre in Bochum in the end of 2019, whose ramp-up exceeded expectations.

OUTLOOK AND OBJECTIVES

In 2020, the management will continue to focus on the integration of the add-on acquisitions into the Group, as well as on winning further hospital cooperations. Further top-line and earnings growth is expected to be fuelled by the expansionary strategy of blikk.

Responsible team member

Lucas Herbert
Lucas Herbert

Managing Director

Lucas Herbert
Name:
Lucas Herbert
Telephone:
+49 69 95787-208
E-Mail:

Lucas Herbert

Managing Director

Lucas Herbert joined Deutsche Beteiligungs AG in 2007 and became a Managing Director in 2015.

Lucas Herbert has twelve years of experience in the private equity sector. During this time, he has gained extensive knowledge, particularly in the IT services/software, mechanical and plant engineering and healthcare sectors. Lucas Herbert has been involved in a large number of corporate investments and disposals. These include Romaco, Spheros, Gienanth and Silbitz. He also led the investment process in blikk and Cloudflight.

He holds a Master of Science in Business Administration from the Rotterdam School of Management, Erasmus University, and also studied at the Maastricht University and the University of Newscastle, Australia.

Current portfolio companies

Former portfolio companies

Lucas Herbert

Managing Director

+49 69 95787-208
lucas.herbert(at)dbag.de